9-(4-Bromophenyl)-10-phenylanthracene | CAS:625854-02-6

We serve 9-(4-Bromophenyl)-10-phenylanthracene CAS:625854-02-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
9-(4-Bromophenyl)-10-phenylanthracene

Chemical Name:9-(4-Bromophenyl)-10-phenylanthracene
CAS.NO:625854-02-6
Synonyms:9-(4-bromophenyl)-10-phenyl-anthracene
Anthracene,9-(4-bromophenyl)-10-phenyl
9-phenyl-10-(4-bromophenyl)anthracene
Molecular Formula:C26H17Br
Molecular Weight:409.31700
 
Physical and Chemical Properties:
Boiling point:161ºC
Flash point:106ºC
 
Specification:
Appearance:Slight yellow solid
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like 9-(4-Bromophenyl)-10-phenylanthracene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,9-phenyl-10-(4-bromophenyl)anthracene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Anthracene,9-(4-bromophenyl)-10-phenyl Use and application,9-phenyl-10-(4-bromophenyl)anthracene technical grade,usp/ep/jp grade.


Related News: The CRL for the Cabenuva injection, containing two active ingredients cabotegravir and Janssen’s rilpivirine, follows U.S. market approval in April for its once-a-day pill Dovato, also a two-drug combination.2-Chlorobenzothiazole manufacturer The CRL for the Cabenuva injection, containing two active ingredients cabotegravir and Janssen’s rilpivirine, follows U.S. market approval in April for its once-a-day pill Dovato, also a two-drug combination.4-[(4,6-dichloropyrimidin-2-yl)amino]benzonitrile supplier With the continuous accumulation of the API industry and the increasing maturity of the market, competition in China’s API industry will become increasingly fierce.9-Chlorononan-1-ol vendor With the continuous accumulation of the API industry and the increasing maturity of the market, competition in China’s API industry will become increasingly fierce.The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries.